JP2016521280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521280A5 JP2016521280A5 JP2016512061A JP2016512061A JP2016521280A5 JP 2016521280 A5 JP2016521280 A5 JP 2016521280A5 JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016521280 A5 JP2016521280 A5 JP 2016521280A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- pharmaceutical composition
- composition according
- cell
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- -1 quinazolinone compound Chemical class 0.000 claims 6
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000010962 ALK-positive anaplastic large cell lymphoma Diseases 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- KXBDTLQSDKGAEB-UHFFFAOYSA-N n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 KXBDTLQSDKGAEB-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819384P | 2013-05-03 | 2013-05-03 | |
| US61/819,384 | 2013-05-03 | ||
| US201361908635P | 2013-11-25 | 2013-11-25 | |
| US61/908,635 | 2013-11-25 | ||
| PCT/US2014/036520 WO2014179661A1 (en) | 2013-05-03 | 2014-05-02 | Methods for treating cancer using combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521280A JP2016521280A (ja) | 2016-07-21 |
| JP2016521280A5 true JP2016521280A5 (enExample) | 2017-06-15 |
Family
ID=50842385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512061A Pending JP2016521280A (ja) | 2013-05-03 | 2014-05-02 | 併用療法を用いて癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9119854B2 (enExample) |
| EP (1) | EP2991651A1 (enExample) |
| JP (1) | JP2016521280A (enExample) |
| TW (1) | TW201534305A (enExample) |
| WO (1) | WO2014179661A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| RU2611007C2 (ru) | 2011-03-11 | 2017-02-17 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US10272083B2 (en) * | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| US20170128448A1 (en) * | 2014-07-11 | 2017-05-11 | Celgene Corporation | Combination therapy for cancer |
| WO2016196580A1 (en) * | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| KR20180023968A (ko) * | 2015-07-02 | 2018-03-07 | 셀진 코포레이션 | 혈액암 및 충실성 종양의 치료를 위한 병용 요법 |
| AU2016326499A1 (en) * | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| TWI782395B (zh) * | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| US10052315B2 (en) * | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| CA3010794A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| KR102735378B1 (ko) * | 2018-11-09 | 2024-11-27 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN113151358B (zh) * | 2020-12-31 | 2024-02-20 | 洛阳市中心医院（郑州大学附属洛阳中心医院） | Znf382稳定转染的弥漫大b细胞淋巴瘤细胞株构建方法及应用 |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| RU2415871C2 (ru) | 2005-03-31 | 2011-04-10 | Байомедикс Инк. | Моноклональное анти-cd20-антитело |
| EP1891113A2 (en) | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| HUE035389T2 (en) * | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| JP5588865B2 (ja) | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｃｄ２０に対するヒト抗体及びその使用方法 |
| US20110243931A1 (en) | 2007-09-02 | 2011-10-06 | Thomas Friess | Combination therapy with type i and type ii anti-cd20 antibodies |
| AU2008305581C1 (en) * | 2007-09-26 | 2014-12-11 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| TWI509247B (zh) | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| PH12013500246A1 (en) * | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| SI2683384T1 (sl) * | 2011-03-11 | 2016-05-31 | Celgene Corporation | Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona |
| WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| JP2014532658A (ja) * | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
-
2014
- 2014-05-02 WO PCT/US2014/036520 patent/WO2014179661A1/en not_active Ceased
- 2014-05-02 JP JP2016512061A patent/JP2016521280A/ja active Pending
- 2014-05-02 US US14/268,439 patent/US9119854B2/en not_active Expired - Fee Related
- 2014-05-02 TW TW103115872A patent/TW201534305A/zh unknown
- 2014-05-02 EP EP14727340.3A patent/EP2991651A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516821A5 (enExample) | ||
| ZA202502152B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2016523974A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| CU20130133A7 (es) | Sales de 2,3- dihidroimidazo[1,2- c] quinazolinas sustituda | |
| MX2016004342A (es) | Formulaciones de (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoi ndolin-2-il)piperidin-2,6-diona. | |
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2014065696A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| ES2688809T3 (es) | Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| BR112019006228A2 (pt) | tratamento de câncer de próstata | |
| JP2016529285A5 (enExample) | ||
| JP2017514806A5 (enExample) | ||
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| RU2014141934A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями | |
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| JP2013528215A5 (enExample) | ||
| WO2016130581A2 (en) | Combination cancer therapy | |
| EP1901745A2 (en) | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor | |
| BRPI0612076A2 (pt) | modulação sinergìstica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase | |
| RU2016140626A (ru) | Комбинация ингибитора EGFR и ингибитора MEK для применения в лечении рака, вызванного мутировавшим NRAS | |
| CN119632992A (zh) | 用于治疗癌症的治疗性组合物和方法 |